SKG 0106
Alternative Names: SKG-0106Latest Information Update: 07 Feb 2024
At a glance
- Originator Skyline Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
- Phase I Diabetic macular oedema
Most Recent Events
- 31 Jan 2024 Phase-I clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT06237777)
- 19 Oct 2023 China National Medical Products Administration (NMPA) approves IND application for SKG 0106 for Wet age-related macular degeneration
- 03 Jul 2023 US FDA approves IND application for SKG 0106 in neovascular age-related macular degeneration